Result of the 2017 Annual General
Meeting
April 25, 2017 – Shire plc
(LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that, at its
Annual General Meeting held at The Merrion Hotel, Upper Merrion
Street, Dublin 2, Ireland at 2.45pm today, all resolutions contained in the
Notice of Meeting were decided by poll vote. The results of the
poll are as follows:
Resolutions |
For (including
discretionary votes) |
% |
Against |
% |
Votes cast as a %
of relevant shares in issue |
Withheld |
Ordinary
Resolutions |
1. To receive the Company’s Annual
Report and Accounts for the year ended December 31, 2016. |
654,818,375 |
98.84% |
7,707,875 |
1.16% |
73.04% |
4,881,183 |
2. To approve the
Directors’ Remuneration Report. |
615,163,095 |
93.22% |
44,723,057 |
6.78% |
72.75% |
7,521,281 |
3. To re-elect Dominic
Blakemore as a Director. |
649,117,820 |
98.05% |
12,928,333 |
1.95% |
72.99% |
5,361,280 |
4. To re-elect Olivier Bohuon as a
Director. |
627,642,447 |
94.87% |
33,920,776 |
5.13% |
72.94% |
5,844,210 |
5. To re-elect William Burns as a
Director. |
665,784,255 |
99.86% |
960,666 |
0.14% |
73.51% |
662,512 |
6. To elect Ian Clark as a
Director. |
651,027,149 |
97.63% |
15,797,431 |
2.37% |
73.52% |
582,853 |
7. To elect Gail Fosler as a
Director. |
661,335,866 |
99.18% |
5,499,058 |
0.82% |
73.52% |
572,509 |
8. To re-elect Steven Gillis as a
Director. |
635,977,566 |
95.40% |
30,649,403 |
4.60% |
73.50% |
780,464 |
9. To re-elect David Ginsburg as a
Director. |
666,231,111 |
99.91% |
593,588 |
0.09% |
73.52% |
582,734 |
10. To re-elect Susan Kilsby as a
Director. |
659,834,334 |
99.01% |
6,565,404 |
0.99% |
73.47% |
1,007,695 |
11. To re-elect Sara Mathew as a
Director. |
660,030,658 |
98.98% |
6,802,836 |
1.02% |
73.52% |
573,939 |
12. To re-elect Anne Minto as a
Director. |
657,515,406 |
99.31% |
4,576,118 |
0.69% |
73.00% |
5,315,909 |
13. To re-elect Flemming Ornskov as
a Director. |
666,498,607 |
99.95% |
322,419 |
0.05% |
73.52% |
586,407 |
14. To re-elect Jeffrey Poulton as a
Director. |
663,597,002 |
99.51% |
3,236,158 |
0.49% |
73.52% |
574,273 |
15. To elect Albert Stroucken as a
Director. |
660,769,699 |
99.09% |
6,047,544 |
0.91% |
73.52% |
590,190 |
16. To re-appoint Deloitte LLP as
the Company’s Auditor. |
596,710,936 |
89.64% |
68,985,657 |
10.36% |
73.39% |
1,710,840 |
17. To authorize the Audit,
Compliance & Risk Committee to determine the remuneration of
the Auditor. |
613,970,704 |
92.24% |
51,651,020 |
7.76% |
73.39% |
1,785,709 |
18. To authorize the allotment of
shares. |
622,880,755 |
93.40% |
43,989,439 |
6.60% |
73.52% |
537,239 |
Special
Resolutions |
19. To authorize the general
disapplication of pre-emption rights. |
647,605,695 |
97.72% |
15,078,442 |
2.28% |
73.06% |
4,723,296 |
20. To authorize the
specific disapplication of pre-emption rights. |
632,770,742 |
95.48% |
29,932,382 |
4.52% |
73.06% |
4,704,309 |
21. To authorize purchases of own
shares. |
658,828,861 |
98.87% |
7,499,007 |
1.13% |
73.46% |
1,079,565 |
22. To adopt new Articles of
Association. |
660,636,265 |
99.08% |
6,130,317 |
0.92% |
73.51% |
640,851 |
23. To approve the notice period for
general meetings. |
619,638,682 |
93.34% |
44,232,588 |
6.66% |
73.19% |
3,536,163 |
As at the record date, April 23,
2017, the Company had 907,025,186 Ordinary Shares of
5 pence each in issue (excluding
shares held in treasury). Shareholders are entitled to one vote per
share. A vote “withheld” is not a vote in law and is not counted in
the calculation of the proportion of votes validly cast.
In accordance with Listing Rule 9.6.2R, copies of the relevant
resolutions passed at the meeting have been submitted to the
National Storage Mechanism and will be available for viewing
shortly at: www.morningstar.co.uk/uk/nsm.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please
contact:
Investor
Relations |
|
|
Ian Karp |
ikarp@shire.com |
+1 781
482 9018 |
Robert Coates |
rcoates@shire.com |
+44 1256
894874 |
Media |
|
|
Lisa Adler |
lisa.adler@shire.com |
+1 617
588 8607 |
Debbi Ford |
debbi.ford@shire.com |
+1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on
serving people with rare diseases. We strive to develop
best-in-class products, many of which are available in more than
100 countries, across core therapeutic areas including Hematology,
Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders,
Gastrointestinal / Internal Medicine / Endocrine and Hereditary
Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to
develop and deliver breakthrough therapies for the hundreds of
millions of people in the world affected by rare diseases and other
high-need conditions, and who lack effective therapies to live
their lives to the fullest.
www.shire.com